Meeting
2022 ASCO Annual Meeting
Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC).
Authors
Andrew Eugene Hendifar
Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA
Andrew Eugene Hendifar , Lee S. Rosen , Andrea Cercek , Autumn Jackson McRee , Atrayee Basu Mallick , David R. Spigel , Sohail F Tavazoie , Eric Keith Rowinsky , Michael Szarek , Foster Gonsalves , Isabel Kurth , Celia Andreu , Robert Busby , Scott Spector , David Martin Darst , Narayan Lebaka , Naftali Bechar , Masoud Tavazoie , Robert Wasserman , Marwan Fakih
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03597581
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3579)
DOI
10.1200/JCO.2022.40.16_suppl.3579
Abstract #
3579
Poster Bd #
373
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
First Author: Meredith Pelster
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).
First Author: Zev A. Wainberg
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill
Poster
2015 ASCO Annual Meeting
A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC).
First Author: Joleen Marie Hubbard